Journal
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Volume 20, Issue 12, Pages 1036-1046Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ijnp/pyx056
Keywords
dopamine; depression; hippocampus; amygdala; ketamine; animal models
Funding
- United States Public Health Service [MH191180]
- Agence Nationale de la Recherche [ANR-15-CE37-0010]
- Agence Nationale de la Recherche (ANR) [ANR-15-CE37-0010] Funding Source: Agence Nationale de la Recherche (ANR)
Ask authors/readers for more resources
Anhedonia is considered a core feature of major depressive disorder, and the dopamine system plays a pivotal role in the hedonic deficits described in this disorder. Dopaminergic activity is complex and under the regulation of multiple brain structures, including the ventral subiculum of the hippocampus and the basolateral amygdala. Whereas basic and clinical studies demonstrate deficits of the dopaminergic system in depression, the origin of these deficits likely lies in dysregulation of its regulatory afferent circuits. This review explores the current information regarding the afferent modulation of the dopaminergic system and its relevance to major depressive disorder, as well as some of the system-level effects of novel antidepressants such as agomelatine and ketamine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available